Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus aspirin on top of clopidogrel or ticagrelor in recent acute coronary syndrome
2014-004266-26Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rivaroxaban, aspirin, clopidogrel and ticagrelor in acute coronary syndrome (ACS) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of participants with TIMI clinically significant bleeding events. Started Jan 2015; status: completed.
02
Drugs
rivaroxabanaspirinclopidogrelticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2014-004266-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004266-26.